RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo Aside from internal R&D efforts, Pfizer plans to find $25 billion in 2030 revenues through external business development. The company struck multiple midsized buyouts in 2022—including the purchases of Biohaven’s migraine franchise for US$11.6 Billion and sickle cell disease player Global Blood Therapeutics for US$54. Billion—and plans plenty more dealmaking, said Albert Bourla, Pfizer's CEO.
" Still, Bourla said he'll avoid a pharma megamerger because it’s “not good for the company right now,” he said. But deals for biotechs of various sizes are on the table. In fact, Bourla said he expects a “portfolio” of deals to meet the company’s dealmaking goals.
On the flip side of this growth outlook, Pfizer needs to overcome $17 billion in patent expirations later this decade, Bourla acknowledged. From 2024 to 2027, Pfizer expects to lose U.S. exclusivity for popular blood thinner Eliquis, immunology med Xeljanz, rare disease med Vynadaqel, plus cancer drugs Ibrance, Inlyta and Xtandi."
https://www.fiercepharma.com/pharma/jpm23-pfizer-entering-most-important-18-month-stretch-company-history-ceo-says